Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMIVAT
2023-510075-63-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated tracheobronchitis (VAT), ventilator-associated pneumonia (VAP) and pulmonary infection comparing Inhaled amikacin with Placebo (2 arms). Primary endpoint: Incidence of transition from ventilator-associated tracheobronchitis (VAT) to ventilator-associated pneumonia (VAP) at Day 28. Planned start Jan 2026; status: authorised.
02
Drugs
amikacin
03
Conditions
ventilator-associated tracheobronchitis (VAT)ventilator-associated pneumonia (VAP)pulmonary infection
Beyond the preview
Go deeper on 2023-510075-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510075-63-00.